Company intelligence / Profile preview

Ascribe Bioscience

Ithaca, New York, United Statesascribebio.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Lead product Phytalix has shown broad-spectrum biopesticide activity in dozens of successful field trials across North America. Trials demonstrated decreased disease pressure and yield benefits equal to or better than best-in-class chemical fungicides. The company collaborates with USDA and university scientists as well as contract research organizations and leading crop protection firms for validation.

Therapeutic areas: Other
Modalities: Small moleculeBiologic
Industry: Agriculture & AgTech

Drug pipeline

1 asset

Phytalix

Pre-commercial

Indications: Crop fungal diseases, Bacterial leaf blight, Plant viral diseases

Partnerships

Collaborations with USDA scientistsUniversity partnerships for field trials (Cornell University/Boyce Thompson Institute)

Beyond the preview

Go deeper on Ascribe Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascribe Bioscience.

Explore the full profile